Beranda Tentang Kami Pelayanan Download Hubungi Kami Indonesia English

dr. A.A. Gde Putra Semara Jaya

Diagnosis dan Tatalaksana Kasus TB
Berdasarkan ISTC

Jumat, 19 Maret 2010Diar PadAnak Dengan Zinc

Dalam rapat monitoring dan evaluasi (monev) Program Pencegahan Penyakit (P2) TB di ruang rapat Dinas Kesehatan Kabupaten Badung pada hari Jumat, 5 Maret 2010, dr. Bagiada, Sp.PD (KP) kembali mengingatkan para tenaga medis, terutama teman sejawat dokter untuk mengikuti International Standards for Tuberculosis Care (ISTC) dalam mendiagnosis dan tatalaksana tuberkulosis. ISTC telah diadopsi oleh pemegang kebijakan di Indonesia pada tahun 2007.

ISTC diciptakan untuk menjawab berbagai permasalahan dalam penanggulangan tuberculosis, yaitu: diagnosis yang tidak standar atau tidak benar, terapi yang tidak standar atau tidak benar, dan tidak adanya tanggungjawab kepada masyarakat.
Dalam ISTC terdapat 17 standar, yang terdiri atas:
• 6 standar diagnosis (penemuan kasus sampai diagnosis)
• 9 standar terapi (tuberkulosis paru, ekstra paru, HIV-TB)
• 2 standar tanggungjawab kesehatan masyarakat (pelaporan, kontak serumah)

Pelaksanaan ISTC di lapangan belum maksimal, terutama oleh pelayanan kesehatan perorangan/swasta. Hal ini terjadi karena sulitnya sosialisasi dilakukan kepada seluruh tenaga medis, terutama para dokter mengenai standar ini. Setiap unit pelayanan yang menangani kasus TB harus berpedoman pada 17 standar ini. Jika merasa sulit untuk memenuhi seluruh standar ISTC di atas, unit pelayanan seyogyanya merujuk kasus tersebut ke unit pelayanan lain yang lebih berkompeten untuk menangani kasus tuberkulosis.

Berikut sekilas 17 standar dalam ISTC.

Standards for Diagnosis
All persons with otherwise unexplained productive cough lasting two–three weeks or more should be evaluated for tuberculosis.
All patients (adults, adolescents, and children who are capable of producing sputum) suspected of having pulmonary tuberculosis should have at least two, and preferably three, sputum specimens obtained for microscopic examination. When possible, at least one early morning specimen should be obtained.
For all patients (adults, adolescents, and children) suspected of having extrapulmonary tuberculosis, appropriate specimens from the suspected sites of involvement should be obtained for microscopy and, where facilities and resources are available, for culture and histopathological examination.
All persons with chest radiographic findings suggestive of tuberculosis should have sputum specimens submitted for microbiological examination.
The diagnosis of sputum smear-negative pulmonary tuberculosis should be based on the following criteria: at least three negative sputum smears (including at least one early morning specimen); chest radiography fi ndings consistent with tuberculosis; and lack of response to a trial of broad-spectrum antimicrobial agents. (NOTE: Because the fluoroquinolones are active against M. tuberculosis complex and, thus, may cause transient improvement in persons with tuberculosis, they should be avoided.) For such patients, if facilities for culture are available, sputum cultures should be obtained. In persons with known or suspected HIV infection, the diagnostic evaluation should be expedited.
The diagnosis of intrathoracic (i.e., pulmonary, pleural, and mediastinal or hilar lymph node) tuberculosis in symptomatic children with negative sputum smears should be based on the fi nding of chest radiographic abnormalities consistent with tuberculosis and either a history of exposure to an infectious case or evidence of tuberculosis infection (positive tuberculin skin test or interferon gamma release assay). For such patients, if facilities for culture are available, sputum specimens should be obtained (by expectoration, gastric washings, or induced sputum) for culture.

Standards for Treatment
Any practitioner treating a patient for tuberculosis is assuming an important public health responsibility. To fulfi ll this responsibility the practitioner must not only prescribe an appropriate regimen but, also, be capable of assessing the adherence of the patient to the regimen and addressing poor adherence when it occurs. By so doing, the provider will be able to ensure adherence to the regimen until treatment is completed.
All patients (including those with HIV infection) who have not been treated previously should receive an internationally accepted fi rst-line treatment regimen using drugs of known bioavailability. The initial phase should consist of two months of isoniazid, rifampicin, pyrazinamide, and ethambutol. The preferred continuation phase consists of isoniazid and rifampicin given for four months. Isoniazid and ethambutol given for six months is an alternative continuation phase regimen that may be used when adherence cannot be assessed, but it is associated with a higher rate of failure and relapse, especially in patients with HIV infection.
The doses of antituberculosis drugs used should conform to international recommendations. Fixed-dose combinations of two (isoniazid and rifampicin), three (isoniazid, rifampicin, and pyrazinamide) and four (isoniazid, rifampicin, pyrazinamide, and ethambutol) drugs are highly recommended, especially when medication ingestion is not observed.
To foster and assess adherence, a patient-centered approach to administration of drug treatment, based on the patient’s needs and mutual respect between the patient and the provider, should be developed for all patients. Supervision and support should be gender-sensitive and age-specifi c and should draw on the full range of recommended interventions and available support services, including patient counseling and education. A central element of the patient-centered strategy is the use of measures to assess and promote adherence to the treatment regimen and to address poor adherence when it occurs. These measures should be tailored to the individual patient’s circumstances and be mutually acceptable to the patient and the provider. Such measures may include direct observation of medication ingestion (directly observed therapy—DOT) by a treatment supporter who is acceptable and accountable to the patient and to the health system.
All patients should be monitored for response to therapy, best judged in patients with pulmonary tuberculosis by follow-up sputum smear microscopy (two specimens) at least at the time of completion of the initial phase of treatment (two months), at five months, and at the end of treatment. Patients who have positive smears during the fifth month of treatment should be considered as treatment failures and have therapy modified appropriately. (See Standards 14 and 15.) In patients with extrapulmonary tuberculosis and in children, the response to treatment is best assessed clinically. Follow up radiographic examinations are usually unnecessary and may be misleading.
A written record of all medications given, bacteriologic response, and adverse reactions should be maintained for all patients.
In areas with a high prevalence of HIV infection in the general population and where tuberculosis and HIV infection are likely to co-exist, HIV counseling and testing is indicated for all tuberculosis patients as part of their routine management. In areas with lower prevalence rates of HIV, HIV counseling and testing is indicated for tuberculosis patients with symptoms and/or signs of HIV-related conditions and in tuberculosis patients having a history suggestive of high risk of HIV exposure.
All patients with tuberculosis and HIV infection should be evaluated to determine if antiretroviral therapy is indicated during the course of treatment for tuberculosis. Appropriate arrangements for access to antiretroviral drugs should be made for patients who meet indications for treatment. Given the complexity of coadministration of antituberculosis treatment and antiretroviral therapy, consultation with a physician who is expert in this area is recommended before initiation of concurrent treatment for tuberculosis and HIV infection, regardless of which disease appeared fi rst. However, initiation of treatment for tuberculosis should not be delayed. Patients with tuberculosis and HIV infection should also receive co-trimoxazole as prophylaxis for other infections.
An assessment of the likelihood of drug resistance, based on history of prior treatment, exposure to a possible source case having drug-resistant organisms, and the community prevalence of drug resistance, should be obtained for all patients. Patients who fail treatment and chronic cases should always be assessed for possible drug resistance. For patients in whom drug resistance is considered to be likely, culture and drug susceptibility testing for isoniazid, rifampicin, and ethambutol should be performed promptly.
Patients with tuberculosis caused by drug-resistant (especially multiple-drug resistant [MDR]) organisms should be treated with specialized regimens containing second-line antituberculosis drugs. At least four drugs to which the organisms are known or presumed to be susceptible should be used, and treatment should be given for at least 18 months. Patient-centered measures are required to ensure adherence. Consultation with a provider experienced in treatment of patients with MDR tuberculosis should be obtained.

Standards for Public Health Responsibilities
All providers of care for patients with tuberculosis should ensure that persons (especially children under 5 years of age and persons with HIV infection) who are in close contact with patients who have infectious tuberculosis are evaluated and managed in line with international recommendations. Children under 5 years of age and persons with HIV infection who have been in contact with an infectious case should be evaluated for both latent infection with M. tuberculosis and for active tuberculosis.
All providers must report both new and retreatment tuberculosis cases and their treatment outcomes to local public health authorities, in conformance with applicable legal requirements and policies.

Klik disini untuk melihat pedoman ISTC



Pemerintah Kabupaten Badung
Dinas Kesehatan
UPT. Puskesmas Kuta I

Jl. Raya Kuta No. 117, Badung, Bali, Indonesia
Telp. (0361) 751311, Fax. (0361) 764735